Table 1.

Demographics

VariableAllABMRTCMRClinicalNoneControl P
No. of patients19791016351270.59
Male sex, n (%)116 (59)5 (56)6 (60)8 (50)24 (69)73 (57)
Race, n (%)
 American Indian or Alaskan native1 (1)0 (0)0 (0)0 (0)1 (3)0 (0)0.09
 Asian5 (3)0 (0)0 (0)0 (0)0 (0)5 (4)
 Black63 (32)6 (67)1 (10)6 (38)12 (34)38 (30)
 Hispanic/Latino22 (11)0 (0)0 (0)2 (12)3 (9)17 (13)
 Native Hawaiian or other Pacific Islander2 (1)0 (0)1 (10)0 (0)0 (0)1 (1)
 Other12 (6)0 (0)0 (0)0 (0)5 (14)7 (6)
 White90 (46)3 (33)7 (70)8 (50)13 (37)59 (46)
Donor type, n (%) 0.27
 Deceased donor127 (64)6 (67)7 (70)10 (62)19 (54)85 (67)
 Living related27 (14)3 (33)1 (10)2 (12)3 (9)18 (14)
 Living unrelated41 (21)0 (0)1 (10)4 (25)12 (34)24 (19)
CMV infection, n (%)3 (2)1 (11)0 (0)0 (0)0 (0)2 (2)0.17
BKV infection, n (%)13 (7)0 (0)1 (10)4 (25)5 (14)3 (2)0.002
DSA, n (%)18 (9)9 (100)2 (20)2 (12)5 (14)0 (0)<0.001
Age at enrollment, mean±SD50±1452±1338±1752±1551±1250±130.11
Days post-transplant at time of biopsy, mean±SD151±153.21024±880.5207±281726.5±446.5108.5±132.4135±119<0.001
HLA class 1 mismatches, mean±SD2.9±1.12.7±1.52.9±1.52.4±1.13.1±12.9±10.28
HLA class 2 mismatches, mean±SD1.3±0.71.1±0.81.2±0.71.1±0.91.4±0.71.2±0.70.48
  • Demographic and clinical information for each of the four biopsy groups plus the control group is provided. ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection; CMV, cytomegalovirus; BKV, BK virus; DSA, donor-specific antibodies.